Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent <i>in vivo</i> antitumor activitySauveur-Michel Maira, Carlos García-Echeverría, Marjo Simonen et al.|Molecular Cancer Therapeutics|2008Cited by 1.1k
Pan-PIM Kinase Inhibition Provides a Novel Therapy for Treating Hematologic CancersPablo D. García, Matthew T. Burger, John L. Langowski et al.|Clinical Cancer Research|2014Cited by 111
Supplementary Figures 1 - 5, Tables 1 - 2 from Pan-PIM Kinase Inhibition Provides a Novel Therapy for Treating Hematologic CancersPablo D. García, Matthew T. Burger, John L. Langowski et al.|Unknown|2023Cited by 0
Supplementary Figures 1 - 5, Tables 1 - 2 from Pan-PIM Kinase Inhibition Provides a Novel Therapy for Treating Hematologic CancersPablo D. García, Matthew T. Burger, John L. Langowski et al.|Unknown|2023Cited by 0
Data from Pan-PIM Kinase Inhibition Provides a Novel Therapy for Treating Hematologic CancersPablo D. García, Matthew T. Burger, John L. Langowski et al.|Unknown|2023Cited by 0